Macro Group Pharmaceuticals - Macro Capital S.A.E results, Q2 2025
Net profit, assets, equity and cash flow for Q2 2025, against the same period a year earlier, from the published financial statements.
Net profit46.53 millionEGP · +176.4% vs the same period a year earlier
In short
- Macro Group Pharmaceuticals - Macro Capital S.A.E's net profit for Q2 2025 was about 46.53 million EGP, up +176.4% from -60.89 million EGP in Q2 2024.
Key lines against the same period a year earlier
This periodQ2 2024Change
Net profit46.53 million-60.89 million+176.4%
Gross profit164 million64.6 million+153.2%
Total assets—517 million—
Total liabilities—490 million—
Shareholders' equity—27.35 million—
Total liabilities and equity—517 million—
Operating cash flow—-30.32 million—
Investing cash flow1.05 million-27.47 million+103.8%
Financing cash flow-31.98 million17.59 million−281.8%
Net change in cash—-40.2 million—
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Macro Group Pharmaceuticals - Macro Capital S.A.E's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy